Why Hospitals Must Prioritize
Genuine and Traceable Medicines
Patient Safety Begins With Responsible Procurement
Hospitals play a critical role in protecting patients from counterfeit, substandard, or improperly stored medicines.
In oncology, immunotherapy, rare diseases, and critical care, even a minor compromise in medicine quality can significantly impact treatment outcomes.
This is why responsible sourcing and traceability are essential responsibilities for hospitals and healthcare institutions.
Risks Associated With Counterfeit or Improperly Sourced Medicines
Healthcare institutions may face serious consequences if medicines are procured through unreliable supply channels.
Potential risks include:
- Treatment failure
- Unexpected adverse reactions
- Reduced drug potency
- Legal and compliance concerns
- Reputational damage
- Increased patient safety incidents
Hospitals must ensure medicines are sourced only through legitimate and documented channels.
Importance of Vendor Verification
Before procuring imported or specialty medicines, hospitals should verify:
Responsible procurement helps minimize risks associated with counterfeit products.
Why Oncology Medicines Require Extra Vigilance
Advanced oncology therapies often involve highly specialized molecules that require precise manufacturing and handling.
Examples include:
Improper storage or counterfeit substitutions may directly affect patient treatment outcomes.
Role of Compliance and Documentation
Maintaining complete procurement documentation supports:
- Regulatory compliance
- Audit readiness
- Patient safety monitoring
- Product recalls if required
- Quality assurance processes
Traceability is an essential component of modern healthcare quality systems.
Final Thoughts
Hospitals serve as a vital line of defense against counterfeit and unsafe medicines.
By prioritizing verified sourcing, proper documentation, and compliant supply channels, healthcare institutions can better protect patients and maintain high standards of care.
📌 Disclaimer: The products mentioned are not approved for commercial sale in India. Access is only provided for personal use under physician supervision, in accordance with CDSCO’s Named Patient Program (Form 12B). MitoGENE does not promote or sell unapproved drugs.